Long non-coding RNAs in multiple myeloma (Review)

被引：8

作者：

Yang, Chenbo ^{[1
,2
]}

Liang, Yinghao ^{[2
,3
,4
]}

Shu, Jiao ^{[1
,2
]}

Wang, Shuaiyuan ^{[1
,2
]}

Hong, Yichen ^{[2
,3
,4
]}

Chen, Kuisheng ^{[1
,2
]}

Sun, Miaomiao ^{[1
,2
]}

机构：

[1] Zhengzhou Univ, Dept Pathol, Affiliated Hosp 1, 1 Jianshe Dong Rd, Zhengzhou 450052, Henan, Peoples R China

[2] Zhengzhou Univ, Henan Key Lab Tumor Pathol, Zhengzhou 450052, Henan, Peoples R China

[3] BGI Coll, Zhengzhou 450052, Henan, Peoples R China

[4] Henan Inst Med & Pharmaceut Sci, Zhengzhou 450052, Henan, Peoples R China

来源：

INTERNATIONAL JOURNAL OF ONCOLOGY | 2023年 / 62卷 / 06期

基金：

中国国家自然科学基金;

关键词：

multiple myeloma; long non-coding RNA; molecular mechanism; tumor progression; prognosis; drug resistance; INTERNATIONAL STAGING SYSTEM; PROMOTES CELL-GROWTH; PROTEASOME INHIBITORS; DRUG-RESISTANCE; WORKING GROUP; PROLIFERATION; EXPRESSION; DISEASE; IDENTIFICATION; PROGRESSION;

D O I：

10.3892/ijo.2023.5517

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple myeloma (MM) is one of the three major malignancies of the hematological system in middle-aged and older individuals. The incidence of MM increases with age and due to its drug resistance and high recurrence, MM seriously harms human health. Long non-coding RNAs (lncRNAs) are RNA molecules with a length of >200 nt and rarely encode proteins. Numerous studies reported that lncRNAs regulate carcinogenesis and cancer progression. MM-associated lncRNAs affect features of tumor cells, including proliferation, apoptosis, adhesion and treatment resistance. The present review aims to summarize the latest findings on the roles of lncRNAs in MM to deepen the understanding of this field and provide insight for developing specific diagnostic tools and effective treatment strategies for MM, including novel biomarkers and targeted lncRNA therapeutics.

引用

页数：16

共 142 条

[1] Circulating Tumour Cells, Cell Free DNA and Tumour-Educated Platelets as Reliable Prognostic and Management Biomarkers for the Liquid Biopsy in Multiple Myeloma [J].

Allegra, Alessandro ;

Cancemi, Gabriella ;

Mirabile, Giuseppe ;

Tonacci, Alessandro ;

Musolino, Caterina ;

Gangemi, Sebastiano .

CANCERS, 2022, 14 (17)

[2] Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity [J].

Amodio, Nicola ;

Stamato, Maria Angelica ;

Juli, Giada ;

Morelli, Eugenio ;

Fulciniti, Mariateresa ;

Manzoni, Martina ;

Taiana, Elisa ;

Agnelli, Luca ;

Cantafio, Maria Eugenia Gallo ;

Romeo, Enrica ;

Raimondi, Lavinia ;

Caracciolo, Daniele ;

Zuccala, Valeria ;

Rossi, Marco ;

Neri, Antonino ;

Munshi, Nikhil C. ;

Tagliaferri, Pierosandro ;

Tassone, Pierfrancesco .

LEUKEMIA, 2018, 32 (09) :1948-1957

[3] Recent Trends in Cancer Genomics and Bioinformatics Tools Development [J].

Anashkina, Anastasia A. ;

Leberfarb, Elena Y. ;

Orlov, Yuriy L. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (22)

[4] Nucleic acid combinations: A new frontier for cancer treatment [J].

Bahadur, Remant ;

Thapa, Bindu ;

Valencia-Serna, Juliana ;

Aliabadi, Hamidreza Montezari ;

Uludag, Hasan .

JOURNAL OF CONTROLLED RELEASE, 2017, 256 :153-169

[5] LncRNADisease 2.0: an updated database of long non-coding RNA-associated diseases [J].

Bao, Zhenyu ;

Yang, Zhen ;

Huang, Zhou ;

Zhou, Yiran ;

Cui, Qinghua ;

Dong, Dong .

NUCLEIC ACIDS RESEARCH, 2019, 47 (D1) :D1034-D1037

[6] DNA Damage, Mutagenesis and Cancer [J].

Basu, Ashis K. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (04)

[7] Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project [J].

Birney, Ewan ;

Stamatoyannopoulos, John A. ;

Dutta, Anindya ;

Guigo, Roderic ;

Gingeras, Thomas R. ;

Margulies, Elliott H. ;

Weng, Zhiping ;

Snyder, Michael ;

Dermitzakis, Emmanouil T. ;

Stamatoyannopoulos, John A. ;

Thurman, Robert E. ;

Kuehn, Michael S. ;

Taylor, Christopher M. ;

Neph, Shane ;

Koch, Christoph M. ;

Asthana, Saurabh ;

Malhotra, Ankit ;

Adzhubei, Ivan ;

Greenbaum, Jason A. ;

Andrews, Robert M. ;

Flicek, Paul ;

Boyle, Patrick J. ;

Cao, Hua ;

Carter, Nigel P. ;

Clelland, Gayle K. ;

Davis, Sean ;

Day, Nathan ;

Dhami, Pawandeep ;

Dillon, Shane C. ;

Dorschner, Michael O. ;

Fiegler, Heike ;

Giresi, Paul G. ;

Goldy, Jeff ;

Hawrylycz, Michael ;

Haydock, Andrew ;

Humbert, Richard ;

James, Keith D. ;

Johnson, Brett E. ;

Johnson, Ericka M. ;

Frum, Tristan T. ;

Rosenzweig, Elizabeth R. ;

Karnani, Neerja ;

Lee, Kirsten ;

Lefebvre, Gregory C. ;

Navas, Patrick A. ;

Neri, Fidencio ;

Parker, Stephen C. J. ;

Sabo, Peter J. ;

Sandstrom, Richard ;

Shafer, Anthony .

NATURE, 2007, 447 (7146) :799-816

[8] Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications [J].

Chauhan, D ;

Anderson, KC .

APOPTOSIS, 2003, 8 (04) :337-343

[9] Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells [J].

Che, Feifei ;

Ye, Xuemei ;

Wang, Yu ;

Ma, Shuyue ;

Wang, Xuemei .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 891

[10] Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives [J].

Chen, D. ;

Frezza, M. ;

Schmitt, S. ;

Kanwar, J. ;

Dou, Q. P. .

CURRENT CANCER DRUG TARGETS, 2011, 11 (03) :239-253

← 1 2 3 4 5 6 7 8 9 10 →